首页 | 本学科首页   官方微博 | 高级检索  
     

前列腺癌根治术后IGRT疗效分析
引用本文:钟秋子,李高峰,修霞,高鸿,徐勇刚,吴钦宏,李明,赵婷. 前列腺癌根治术后IGRT疗效分析[J]. 中华放射肿瘤学杂志, 2016, 25(6): 583-587. DOI: 10.3760/cma.j.issn.1004-4221.2016.06.009
作者姓名:钟秋子  李高峰  修霞  高鸿  徐勇刚  吴钦宏  李明  赵婷
作者单位:100730 北京医院放疗科
基金项目:国家自然科学基金(81372415
摘    要:目的 分析前列腺癌根治术后辅助性及挽救性放疗的临床疗效、不良反应,同时对PSA变化水平和意义进行分析。方法 回顾分析2008—2015年间收治的前列腺癌根治术后行放疗患者58例资料(IGRT 50例,IMRT 8例),辅助性放疗21例,挽救性放疗 37例。前列腺精囊95%PTV中位处方剂量为74 Gy,盆腔95%PTV中位处方剂量为50 Gy。Kaplan-Meier方法计算生存率,Pearson法行相关分析。结果 中位随访36.2个月。3年BRFS率为82%,3年OS率为96%。全组PSA放疗后降至最低点的中位时间为3个月,平均值为0.04 ng/ml。辅助性放疗前PSA中位数0.034 ng/ml,手术至放疗中位时间5.4个月,放疗后PSA降至最低点平均需4.6个月。挽救性放疗前PSA中位数0.540 ng/ml,手术至放疗中位时间69.7个月,放疗后PSA降至最低点平均需9.4个月。1、2级急性泌尿生殖和胃肠道反应发生率分别为55%、2%和30%、8%;1、2级晚期泌尿生殖和胃肠道反应发生率分别为10%、16%和9%、3%。直肠D50与早晚期胃肠道反应发生率明显相关(P=0.012、0.026)。结论 辅助性放疗比挽救性放疗PSA降至最低点时间短,二者早期晚期不良反应小。

关 键 词:前列腺肿瘤/术后放射疗法   放射疗法  图像引导   放射疗法  辅助性   放射疗法  挽救性   前列腺特异抗原   不良反应  
收稿时间:2015-09-15

Efficacy of adjuvant and salvage image-guided radiotherapy in post-radical prostatectomy patients
Zhong Qiuzi,Li Gaofeng,Xiu Xia,Gao Hong,Xu Yonggang,Wu Qinhong,Li Ming,Zhao Ting. Efficacy of adjuvant and salvage image-guided radiotherapy in post-radical prostatectomy patients[J]. Chinese Journal of Radiation Oncology, 2016, 25(6): 583-587. DOI: 10.3760/cma.j.issn.1004-4221.2016.06.009
Authors:Zhong Qiuzi  Li Gaofeng  Xiu Xia  Gao Hong  Xu Yonggang  Wu Qinhong  Li Ming  Zhao Ting
Affiliation:Department of Radiation Oncology,Beijing Hospital,Beijing 100730,China
Abstract:Objective To analyze the clinical efficacy and toxicity of adjuvant (ART) and salvage radiotherapy (SRT) after prostatectomy for prostate careinoma,and to investigate the variation and significance of prostate-specific antigen (PSA) level.Methods A retrospective study was performed on the clinical data of 58 patients receiving intensity-modulated radiotherapy after prostatectomy from November 2008 to August 2015.In those patients,21 received ART and 37 SRT.The median dose delivered to the 95% planning target volume (PTV) of the prostate and seminal vesicles tumor bed was 74 Gy,and 95% PTV of the pelvic lymph nodes was 50 Gy.The survival rate was calculated by Kaplan-Meier method.Used Pearson correlation analysis.Results The median follow-up time was 36.2 months.The 3-year biochemical relapse-free survival,tumor-specific survival,and overall survival rates were 81.8%,100%,and 96%,respectively.In all patients,the median time to PSA nadir after radiotherapy was 3 months with a mean level of PSA nadir of 0.04 ng/ml.In patients treated with ART,the median PSA level before radiotherapy was 0.034 ng/ml;the median time from surgery to radiotherapy was 5.4 months;the mean time to PSA nadir after radiotherapy was 4.6 months.In patients treated with SRT,the median PSA level before radiotherapy was 0.540 ng/ml;the median time from surgery to radiotherapy was 69.7 months;the mean time to PSA nadir after radiotherapy was 9.4 months.The incidence rates of grade 1 and 2 short-term genitourinary (GU)toxicity were 55% and 2%,respectively,while the incidence rates of grade 1 and 2 long-term GU toxicity were 10% and 16%,respectively.The incidence rates of grade 1 and 2 short-term gastrointestinal (GI)toxicity were 30% and 8%,respectively,while the incidence rates of grade 1 and 2 long-term GI toxicity were 9% and 3%,respectively.No patients had grade 3 or 4 toxicity.Rectum D50 was significantly related with acute and late GI side effects (P=0.012、0.026).Conclusions Both ART and SRT achieve satisfactory treatment outcomes and low short-and long-term toxicity.Compared with ART,SRT has a longer time to PSA nadir.
Keywords:Prostate neoplasms/postoperative radiotherapy  Radiotherapy,image-guided  Radiotherapy,adjuvant  Radiotherapy,salvage  Prognosis  Prostate-specific antigen  Untoward effect
本文献已被 万方数据 等数据库收录!
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号